We demonstrated that impaired cardiac contractility (decreased LVEF) as well as nocturnal hypoxia (decreased mean SpO2) are independently associated with an increased myocardial MARK4 expression, thereby suggesting MARK4 as a potential molecular target for heart failure therapy. The gene discussed is MARK4; the disease is heart failure.